Rapport Therapeutics, Inc. Common Stock

NASDAQ:RAPP

Biotechnology

Healthcare
$23.40 +0.05%

+$0.02 today

Market cap
$1.12B
Beta
0.98
P/E (TTM)
-16.2
EPS (TTM)
-$2.27
52W Low $10.51High $42.27

Volume 0.73M

Average 0.33M

RAPP Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin at 98.9%

Gross margin was 98.9% in Q1 FY2026. On a trailing-twelve-month basis it was 95.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
98.9%— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
95.0%— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

No Gross Margin data reported for this period type.

Gross Margin vs competitors

How RAPP compares with its peers on the latest reported figures

  • RAPP's LTM Mar 2026 gross margin of 95.0% is the highest of the 3 companies compared; the peer median is 79.1%.
RAPP Competitors Peer median
Gross Margin for RAPP and competitors
Company Period LTM level YoY 3-year change
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 202695.0% ——
AXSMAxsome Therapeutics, Inc.LTM Jun 202693.2% +1.8 pp+3.0 pp
ACADACADIA Pharmaceuticals Inc.LTM Sep 202664.9% -27.0 pp-6.3 pp
PRAXPraxis Precision Medicines, Inc.FY2025— ——
LBRXLB Pharmaceuticals Inc Common StockFY2025— ——
ANROAlto Neuroscience, Inc.FY2025— ——
SPTXSeaport Therapeutics, Inc. Common Stock—— ——
CTNMContineum Therapeutics, Inc. Class A Common StockFY2025— ——
MPLTMapLight Therapeutics, Inc.FY2025— ——
NMRANeumora Therapeutics, Inc. Common StockFY2025— ——
CGTXCognition Therapeutics, Inc.FY2025— ——
Peer median (excluding RAPP) 79.1%-12.6 pp-1.7 pp

Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue15K112K839K1.02M
Gross Profit(15K)(112K)(839K)(1.02M)
Gross Margin————
Research & Development9.12M28M60.94M94.79M
Selling, General & Admin1.37M8.07M22.12M30.31M
Operating Expenses10.35M36.07M82.22M125.1M
Depreciation & Amortization15K112K839K1.02M
EBITDA(10.35M)(34.66M)(77.47M)(124.08M)
EBITDA Margin————
Operating Income(10.37M)(36.18M)(83.06M)(125.1M)
Operating Margin————
Interest Income02.53M12.14M13.62M
Interest Expense285K000
Other Income / Expenses(285K)1.4M4.75M13.62M
Income Before Tax(10.65M)(34.78M)(78.31M)(111.48M)
Pre-Tax Margin————
Income Tax Expense010K00
Net Income(10.65M)(34.79M)(78.31M)(111.48M)
Net Margin————
EPS (Basic)(0.29)(0.95)(3.78)(2.86)
EPS (Diluted)(0.29)(0.95)(3.78)(2.86)
Weighted Avg Shares20.12M18.08M20.74M46.98M
Weighted Avg Shares (Diluted)20.12M18.08M20.74M46.98M

Rapport Therapeutics, Inc. Common Stock

NASDAQ:RAPP

Intrinsic Alpha fair value

Locked

Current Price

$23.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.